Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor
| Autor: | Sung Sook Lee, Yoon-Koo Kang, Min-Hee Ryu, Hyoungnam Lee, Jae-Lyun Lee, Tae Won Kim, Sun Jin Sym, Geundoo Jang, Heung Moon Chang, Inkeun Park |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Receptor Platelet-Derived Growth Factor alpha Gastrointestinal Stromal Tumors DNA Mutational Analysis Urology Antineoplastic Agents Piperazines Stable Disease Asian People Medicine Humans Radiology Nuclear Medicine and imaging Dosing Treatment Failure Stromal tumor Neoplasm Metastasis neoplasms Survival rate Aged Retrospective Studies Korea GiST business.industry Retrospective cohort study Imatinib General Medicine Middle Aged Surgery Survival Rate Proto-Oncogene Proteins c-kit Imatinib mesylate Pyrimidines Oncology Benzamides Disease Progression Imatinib Mesylate Female business medicine.drug |
| Zdroj: | Japanese journal of clinical oncology. 39(2) |
| ISSN: | 1465-3621 |
| Popis: | Objective: We evaluated the results of imatinib dose escalation in patients with advanced gastrointestinal stromal tumors (GISTs) after disease progression on standard-dose imatinib. Methods: Clinical data from patients with metastatic or unresectable GISTs whose dose of imatinib was increased after disease progression on imatinib 400 mg/day were retrospectively reviewed. Results: The 24 patients studied had a median age of 52 years. Imatinib dosing was escalated to 600 mg/day in 12 patients, then to 800 mg/day in four patients. The other 12 patients had dose escalation directly to 800 mg/day. Two patients (8.3%) achieved a partial response, and seven (29.2%) had stable disease. Six-month progression-free and overall survival rates were 33.3 and 70.7%, respectively. Dose escalation to 600 or 800 mg/day was generally well tolerated. Conclusion: Imatinib dose escalation is feasible and well tolerated in patients with advanced GIST who progress on standard-dose therapy, producing clinical benefit in 37% of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|